National University Hospital
Singapore, 119074
NCT Number: NCT00786591
Acute pancreatitis refers to inflammation of the pancreas and is associated with sudden onset of severe abdominal pain, often accompanied by transient systemic manifestations, including fever. In the majority of cases, the inflammatory process is self limiting and patient recovers uneventfully; however, in about 20% to 30% of the cases, a protracted clinical course ensues and the disease may progress to a severe necrotizing form, often triggering a systemic inflammatory response syndrome during which time, acute respiratory distress syndrome, renal failure, shock, and disseminated intravascular coagulation may occur. In the worst sequelae, multiple organ dysfunctions may follow and death supervene. The clinical outcome of patients suffering from severe acute pancreatitis depends to a great extent on the early diagnosis and prediction of severity and timely therapeutic intervention to prevent local and systemic complications. However, the course of the disease is often difficult to predict from the outset. Currently, there is still no single clinical or laboratory test that can be considered the "gold standard" for diagnosis and/or assessment of severity of acute pancreatitis. For a disease that may progress rapidly without apparent sign, the ideal marker for the prediction of disease severity in a patient would be one that is measurable rapidly and easily, besides being able to fulfill all the other criteria required of a good biological marker. To identify such a potential marker for acute pancreatitis requires understanding of the pathophysiological process underlying the rapid progression of a fulminant course of the disease. Although much remains to be elucidated, recent studies in animals have suggested that inflammatory mediators substance P and hydrogen sulfide may play critical roles. This study will evaluate if inflammatory mediators substance P and hydrogen sulfide are upregulated early on in the disease process, and if the levels of their elevation predict disease severity.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Singapore, 119074
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The patient should fulfill all of the following criteria:
Exclusion criteria
The patient should not present any of the following criteria:
Time frame: On admission to hospital, blood sampling will be done every 6 hours for 3 days
Time frame: Within 3 days of hospital admission
National University Hospital, Singapore
Other
Clinical Evaluation of Novel Biological Markers for the Prediction of Severe Acute Pancreatitis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07712081
Acute Pancreatitis, Digestive System Diseases
Rui’an, Zhejiang, China
View Trial DetailsNCT05651360
Abdominal Pain, Acute Appendicitis
Odense, Denmark
View Trial DetailsNCT05201053
Acute Pancreatitis, Digestive System Diseases
Malmö, Skåne County, Sweden
View Trial DetailsNCT03401190
Acute Pancreatitis, Digestive System Diseases
Detroit, Michigan, United States
View Trial Details